NEW YORK (TheStreet) -- Shares of Inovio Pharmaceuticals (INO) - Get Report are jumping 12.1% to $6.02 on Thursday afternoon as the company begins patient recruitment for its MERS vaccine trial with GeneOne Life Science.
This trial is the first MERS vaccine to be tested in humans for the disease, which has no approved vaccines or treatments, the company said in a statement this morning.
The Middle East Respiratory Syndrome is a viral respiratory illness, which can cause fever, cough and shortness of breath. The virus has triggered widespread outbreaks and deaths in the Middle East and Korea.
San Diego-based Inovio develops DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
"Our broad experience with DNA-based immunotherapies and with MERS specifically suggests we can potentially make an important contribution to developing such a solution," Inovio President and CEO Dr. J. Joseph Kim said in a statement.
GeneOne Life Science, a South Korea-based biopharmaceutical company, is co-developing Inovio's MERS vaccine.
Additionally, the companies announced last week they would collaborate on a vaccine for the Zika virus.
Separately, TheStreet Ratings Team has a "sell" rating with a score of D+ on the stock.
This is driven by a number of negative factors, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered by the team.
The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: INO